We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Richmond's Neurobiological Technologies signed deals with two other companies
to make and package its ischemic stroke drug for upcoming Phase III trials.
Introgen Therapeutics has announced a patent that directly covers
many of the special features of its Advexin molecular therapy, has been awarded
by the U.S. Patent and Trademark Office.
Sanofi-aventis has announced that the FDA has accepted for filing the company's
New Drug Application (NDA) for rimonabant, the first agent in a new therapeutic
class known as selective cannabinoid type 1 (CB1) blockers.
The FDA has granted Novartis priority review status for its new drug application
for Exjade (deferasirox), a once-daily oral iron chelator for the treatment
of chronic iron overload resulting from blood transfusions.
Neurocrine has announced that data presented this week at the Associated
Professional Sleep Societies' Annual Meeting showed that indiplon safely and
effectively helps elderly patients with chronic insomnia fall asleep faster
and stay asleep throughout the night.
Scientists at The Scripps Research Institute have solved the structure
of a crucial human immune system molecule called TLR3, an acronym for Toll-like
receptor three.
Theresa Mitchell, vice president of regulatory and clinical affairs for Oculus
Innovative Sciences, has announced that Oculus has initiated its first U.S.
clinical trial on humans to gain approval for the Microcyn Technology to be
marketed as an antimicrobial preoperative and preinjection skin preparation.
Point Therapeutics has announced that it has initiated a Phase II
clinical trial of the company's lead therapeutic compound, Talabostat, for the
treatment of metastatic pancreatic cancer.
Avanir has announced the initiation of a double-blind, placebo-controlled,
multicenter, Phase III clinical trial of Neurodex in patients with diabetic
neuropathic pain.